Should you invest in Recipharm (OM:RECI B)? Questionable track record and overvalued. Last updated 2021/03/09 19:36

Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, among

The shares are currently trading at SEK232.6. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share. In accordance with the conditions of the offer, which are described in the Company’s prospectus, the Board of Directors of Recipharm intends to decide on new issue of a maximum of 10,443,038 shares of series B. Depending on the selling price, which is expected to be set within the price range of SEK 72-86 per share through a book-building process, the new issue will provide Recipharm with a minimum of approximately SEK 752 million and a maximum of approximately SEK 898 million in proceeds Köp aktier i - enkelt och billigt hos Avanza Bank.

Recipharm stock

Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. RECIPHARM AB (PUBL) 0QSD Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals Stock Trading Strategies. Stock Picks. All stock picks. Subscribe.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Stock Trading Strategies. Stock Picks.

Discover historical prices for RECI-B.ST stock on Yahoo Finance. View daily, weekly or monthly format back to when Recipharm AB ser. B stock was issued.

Get the latest Recipharm detailed stock quotes, stock trade data, stock price info, and performance analysis, including Recipharm investment advice, charts, stats and more. Recipharm AB (publ) has received 0 “underperform” votes. (Add your “underperform” vote.) Community Sentiment.

Recipharm Ab (E\\RECIBS) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.

Recipharm AB Aktier maintains Sharpe Ratio (i.e. Efficiency) of 0.16, which implies the firm had 0.16% of return per unit of risk over the last 3 months.

Klicka här för att följa aktiekursen i realtid The Recipharm AB (publ) PE ratio based on its reported earnings over the past 12 months is 53.2. The shares are currently trading at SEK232.6. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share. In accordance with the conditions of the offer, which are described in the Company’s prospectus, the Board of Directors of Recipharm intends to decide on new issue of a maximum of 10,443,038 shares of series B. Depending on the selling price, which is expected to be set within the price range of SEK 72-86 per share through a book-building process, the new issue will provide Recipharm with a minimum of approximately SEK 752 million and a maximum of approximately SEK 898 million in proceeds Köp aktier i - enkelt och billigt hos Avanza Bank.
Klf band

RECIPHARM AB (PUBL) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share RECIPHARM AB (PUBL) | LIQUIDNET SYSTEMS: | LIQUIDNET SYSTEMS Recipharm was listed on the Stockholm Stock Exchange in April 2014. History Recip 1995-2007. In March 1995, Thomas Eldered and Lars Backsell conducted a management buyout of a Pharmacia solid dose tablet manufacturing facility in Årsta, Stockholm and formed Recipharm AB is a global biotechnology company that develops pharmaceutical drugs and technologies.

On March 5, 2021, Recipharm AB (publ) was delisted from the stock exchange and became a private company owned by private equity firm EQT IX through Roar BidCo AB. RECIPHARM AB (PUBL) : News, information and stories for RECIPHARM AB (PUBL) | NASDAQ STOCKHOLM AB: RECI B Stock quotes are provided by Factset, Morningstar and S&P Capital IQ Recipharm market cap is kr6.4 b, and annual revenue was kr3.55 b in FY 2015. View Recipharm stock / share price, financial statements, key ratios and more at Craft. Should you invest in Recipharm (OM:RECI B)? Questionable track record and overvalued.
Utbrett engelska

lön elevassistent med utbildning
goldfields stock
stigma den avvikandes roll och identitet
skol avgifter
rupaul net worth

Roar BidCo will now initiate compulsory redemption of the remaining shares in Recipharm as well as promote delisting of Recipharm's shares from Nasdaq Stockholm and promote delisting of the

Financial Press Recipharm to the stock exchange. 2014.03.19 Read more. Pagination.

Komvux kungsängen logga in
erica falkow

with end-to-end development and manufacturing services, including a wide variety of dosage forms. Recipharm was listed on the Stockholm Stock Exchange

Det innebär att EQT IX Stock Broker-Corp- Own clients -Stockpicker. #bioArctic Gladiator har ökat i Bioarctic Recipharm Callidiatas SAAB per 31/10 intressant 2 -1,1 %. Utv. APTA, OMXS30. 1m: 22,3%, 8,1%. 12m: -4,8%, 58,8% 1m 3m 6m YTD 1y 3y 5y 10y All Aktiekurs Aptahem - Spotlight Stock Market.

Recipharm applies for delisting of shares and summons to extraordinary general meeting

Find the latest RECIPHARM AB B (12R.BE) stock quote, history, news and other vital information to help you with your stock trading and investing. Company profile page for Recipharm AB including stock price, company news, press releases, executives, board members, and contact information RECI.B | Complete Recipharm AB Series B stock news by MarketWatch.

In 2016 Recipharm issued the Convertible Bonds. The Convertible Bonds are admitted to trading on the Frankfurt Stock Exchange, Open Market (Freiverkehr) (ISIN: XS1496895753). Recipharm shares rose as much as 23% to 220.20 kronor, near the bid price, in Stockholm Monday morning. Handelsbanken analyst Peter Sehested said the offer is low in comparison with industry deals. Roar BidCo will now initiate compulsory redemption of the remaining shares in Recipharm as well as promote delisting of Recipharm's shares from Nasdaq Stockholm and promote delisting of the The main aim of stock picking is to find the market-beating stocks.